Abiopharma

ESTRELLA IMMUNOPHARMA, INC. (ESLA)

Symbol	ESLA
Name	ESTRELLA IMMUNOPHARMA, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Biological Products (No Diagnostic Substances)
Address	5858 HORTON STREET,SUITE 370, EMERYVILLE, California, 94608, United States
Telephone	+1 510 - 318-9098
Fax	—
Email	—
Website	https://www.estrellabio.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001844417
Description	Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eurekas ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eurekas ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). Additional info from NASDAQ: Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eurekas ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eurekas ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

2026-05-05 12:00

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

2026-04-30 18:28

New Form 10-K/A - Estrella Immunopharma, Inc. Filed: 2026-04-30 AccNo: 0001213900-26-050433 Size: 504 KB

2026-04-30 01:36

Xu Jiandong 🟢 acquired 2.1K shares of Estrella Immunopharma, Inc. (ESLA) at $1.33 Transaction Date: Sep 11, 2025 | Filing ID: 049602

2026-03-23 12:00

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

2026-02-13 19:28

New Form 424B3 - Estrella Immunopharma, Inc. Filed: 2026-02-13 AccNo: 0001213900-26-016605 Size: 6 MB

2026-02-09 12:00

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

2026-01-15 02:44

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

2026-01-15 02:44

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

2026-01-14 19:19

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

2026-01-14 19:19

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

No clinical trials found for this company.

No clinical products found for this company.